Search Results
Nov 06, 2025, 14:00 ET Academy Sports + Outdoors Unwraps this Holiday Season's Top Gifts Delivering Legendary Value and Undefeatable Prices
Academy Sports + Outdoors ("Academy" or the "Company") (Nasdaq: ASO) is making it easier than ever for families to create lasting memories without breaking the bank. With unbeatable deals on top brands, a wide assortment
More news about: Academy Sports + Outdoors
Nov 04, 2025, 09:00 ET Abbott HeartMates Community Delivers Holiday Cheer in Hallmark Channel's New Movie "The More the Merrier"
https://abbo.tt/ASO_ISI. For U.S. Important Safety Information about the Masters mechanical heart valve, visit
More news about: Abbott
Oct 21, 2025, 08:23 ET Hoth Therapeutics Reports FDA Orphan Drug Designation and Strong Preclinical Data for HT-KIT in Rare c-KIT-Driven Cancers
expression and significant tumor-volume reduction by Day 8 in systemic mastocytosis and GIST models. HT-KIT, a precision antisense oligonucleotide (ASO) targeting KIT mRNA, also completed GLP-validated bioanalytical methods supporting IND-enabling studies; Japan Patent No. 7677628 extends platform protection
More news about: Hoth Therapeutics, Inc.
Oct 09, 2025, 10:06 ET It's Croctober at Academy Sports + Outdoors: Celebrate With Your Favorite Styles During Crocs Week
Nasdaq: ASO) is stepping out in style all month long in celebration of Croctober. Whether you're a fan of the
More news about: Academy Sports + Outdoors
Oct 07, 2025, 11:20 ET Neuromuscular Disease Therapeutics Market to Reach US$ 45.62 Billion by 2033 as Gene Therapies and RNA-based Treatments Redefine Patient Outcomes
reimbursement frameworks for rare disease drugs. Recent update (2025): Biogen received FDA approval for a next-generation ASO targeting ALS progression. Japan Japan's
More news about: DataM Intelligence 4 Market Research LLP
Oct 07, 2025, 11:00 ET Rare Disease Therapeutics Market to Surpass US$ 495.27 Billion by 2033 as Gene Therapy, RNA-based Drugs, and Biologics Transform Patient Care
one-time treatments will revolutionize patient outcomes. RNA-based Leadership – mRNA, RNAi, and ASO platforms will expand across neuromuscular and metabolic rare diseases. AI-enabled Precision Medicine –
More news about: DataM Intelligence 4 Market Research LLP
Oct 07, 2025, 10:06 ET Academy Sports + Outdoors Celebrates "Brooks Month" with Exclusive Launch of Hero Collection
Nasdaq: ASO), a leading full-line sporting goods and outdoor recreation retailer, is celebrating "Brooks Month" all October-long. Adding to the lineup of Brooks
More news about: Academy Sports + Outdoors
Oct 02, 2025, 08:55 ET Academy Sports + Outdoors Continues Pursuit of Becoming the Best Sports + Outdoors Retailer in the Country
Nasdaq: ASO), is well on its way after going public in 2020. The Company's growth strategy is rooted in opening new stores, investing in the e-commerce experience
More news about: Academy Sports + Outdoors
Oct 01, 2025, 13:33 ET Mark Farrah Associates Assessed Second Quarter Health Insurance Membership Trends
from 2Q24. The Employer-group risk and Employer-group ASO segments provide the largest sources of coverage in the industry, however, while Employer-group ASO saw an enrollment increase of 1.2%, the Employer-group risk market experienced year-over-year membership
More news about: Mark Farrah Associates (MFA)
Sep 22, 2025, 11:16 ET RNA-based Therapies Market to Reach USD 213.54 Billion by 2033, Driven by Rare Diseases, Oncology, and Advances in RNA Technologies | DataM Intelligence
between Japanese firms and global biopharma for RNAi and ASO therapies.PMDA's regulatory flexibility, supporting clinical trials for RNA-based therapies targeting rare and genetic diseases.In 2025, NS Pharma advanced multiple ASO-based therapies into late-stage trials, reinforcing
More news about: DataM Intelligence 4 Market Research LLP
Sep 21, 2025, 20:29 ET AusperBio Raises $63 Million in Series B2 Financing to Accelerate Functional Cure Therapies for Chronic Hepatitis B
Med-OligoTM ASO platform which has been shown to substantially enhance the current ASO therapeutics, through novel insights into ASO design. Combining efficient targeted delivery conjugation technologies, the modular Med-OligoTM Platform empowers ASO therapeutics to treat
More news about: AusperBio Therapeutics Inc.
Sep 18, 2025, 20:33 ET AusperBio Completes Enrollment in Two Phase II Clinical Trials of AHB-137 for Chronic Hepatitis B
proprietary Med-Oligo™ ASO platform which has been shown to substantially enhance the current ASO therapeutics, through novel insights into ASO design. Combining with efficient targeted delivery conjugation technologies, the modular Med-Oligo™ Platform empowers ASO therapeutics to treat a
More news about: AusperBio Therapeutics Inc.
Sep 03, 2025, 07:15 ET SpliSense Reports Positive Results from Phase 2 Study of SPL84 in Cystic Fibrosis
diseases, today announced positive results from SPL84-002, its ongoing global Phase 2 study evaluating SPL84, the Company's lead antisense oligonucleotide (ASO), for the treatment of people with cystic fibrosis (CF) carrying the 3849+10 kilobase (Kb) C->T splicing mutation in the CFTR gene. The SPL84-002
More news about: SpliSense
Aug 29, 2025, 16:30 ET Academy Sports + Outdoors Announces Quarterly Cash Dividend
Academy Sports and Outdoors, Inc. (the "Company" or "Academy") (Nasdaq: ASO) announced today that on August 28, 2025, its Board of Directors declared a quarterly cash dividend with respect to the
More news about: Academy Sports + Outdoors
Aug 29, 2025, 08:55 ET Academy Sports + Outdoors Announces Participation in Upcoming Investor Conference
Nasdaq: ASO) today announced its participation in the upcoming Goldman Sachs 32nd Annual Global Retailing Conference 2025 to be held Wednesday, September 3 to
More news about: Academy Sports + Outdoors
Aug 28, 2025, 09:05 ET Academy Sports + Outdoors Accelerates Growth with Eleven New Stores Opening in Third Quarter 2025
Nasdaq: ASO), a leading full-line sporting goods and outdoor recreation retailer, is excited to announce it has opened three new locations in
More news about: Academy Sports + Outdoors
Aug 28, 2025, 07:00 ET Vanda Pharmaceuticals Announces FDA Granted Orphan Drug Designation for VGT-1849B, a Novel and Selective Candidate for the Treatment of Polycythemia Vera
the United States is estimated to affect 44 to 57 per 100,000 people.2 VGT-1849B is an antisense oligonucleotide (ASO) that utilizes a novel backbone chemistry, OliPass Peptide Nucleic Acid (OPNA), that has been derived from peptide nucleic acid (PNA) by rationally introducing
More news about: Vanda Pharmaceuticals Inc.
Aug 27, 2025, 07:00 ET Leal Therapeutics Announces $30 Million Series A to Progress First-In-Class Neuro-Metabolic Therapies for Neurodegenerative and Neuropsychiatric Disorders with High-Unmet Need
clinical study of LTX-001 support safety and effective target engagement. Leal is also developing LTX-002, a near-clinical stage antisense oligonucleotide (ASO) for patients with genetic or sporadic ALS. LTX-002 targets the de novo synthesis of ceramides/sphingolipids by inhibiting the first and rate-limiting
More news about: Leal Therapeutics
Aug 21, 2025, 08:55 ET Academy Sports + Outdoors Announces Second Quarter Fiscal 2025 Results Conference Call
Nasdaq: ASO), a leading full-line sporting goods and outdoor recreation retailer, plans to release its second quarter fiscal 2025 financial results before the market
More news about: Academy Sports + Outdoors
Aug 19, 2025, 06:30 ET Early Success of Pager Health℠ Navigator Shows How Plans Optimize ASO Performance
outcomes while lowering overall healthcare costs, reinforcing the value health plans can deliver through their ASO products. Purpose-Built for Today's ASO Market Pager Health's ASO solution is engineered to address the unique needs of commercial health plans and their employer clients:
More news about: Pager Health
Aug 15, 2025, 07:00 ET Novel Gene Therapy for ALS cleared for global trials in China and the U.S.
Medicine. SineuGene leverages cutting-edge technologies, such as adeno-associated virus (AAV) mediated gene delivery and antisense oligonucleotide (ASO) based gene regulation, to develop a robust pipeline targeting central nervous system disorders including ALS, Stroke, Parkinson's Disease, Alzheimer's
More news about: SineuGene Therapeutics
Aug 07, 2025, 16:10 ET Evolent Announces Second Quarter 2025 Results
Fee Performance Suite Lives on Platform are calculated by summing monthly members covered for specialty care services for contracts not under ASO arrangements, plus members managed by Complex Care in capitation arrangements and divided by the number of months in the period. Specialty Technology
More news about: Evolent Health, Inc.
Aug 05, 2025, 09:05 ET Academy Sports + Outdoors Announces Executive Appointment
Nasdaq: ASO), a leading full-line sporting goods and outdoor recreation retailer today announced the appointment of Brandy Treadway
More news about: Academy Sports + Outdoors
Jul 21, 2025, 15:45 ET AusperBio Receives China CDE Clearance to Advance AHB-137 into Phase III Clinical Trial for Chronic Hepatitis B
Med-Oligo™ ASO platform which has been shown to substantially enhance the current ASO therapeutics, through novel insights into ASO design. Combining with efficient targeted delivery conjugation technologies, the modular Med-Oligo™ Platform empowers ASO therapeutics to treat
More news about: AusperBio Therapeutics Inc.
Jun 26, 2025, 10:04 ET SineuGene's SNUG01 Receives FDA Orphan Drug Designation for ALS
Medicine. SineuGene leverages cutting-edge technologies, such as adeno-associated virus (AAV)-mediated gene delivery and antisense oligonucleotide (ASO)-based gene regulation, to develop a robust pipeline targeting central nervous system disorders including ALS, stroke, Parkinson's disease, Alzheimer's
More news about: SineuGene Therapeutics